Opinion

Video

Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment

Author(s):

Nathalie Albert, MD ,Matthias Preusser, MD

Medical experts engage in a discussion on the PET RANO 1.0 Response Criteria, which provides guidelines for evaluating treatment response in patients with brain tumors, taking into account both measurable PET-positive disease and non-PET-positive disease, as assessed through initial baseline imaging and subsequent follow-up scans.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Malignant Glioma
November 7th 2024

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

FDA
October 24th 2024

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

Panna Sharma
October 15th 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

Randall B. Riggs, MBA
October 11th 2024

FDA Grants Orphan Drug Designation to LMP744 for Glioma

MTX110 in Recurrent Glioblastoma | Image Credit: © Dr_Microbe - stock.adobe.com
October 4th 2024

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma